Science, Computers & Technology, Intellectual Property, Health Law

Rubin v. General Hospital Corp. (Fed. Cir. 2013)

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 5/8/2013

On March 28, the Federal Circuit in Rubin v. General Hospital Corp. affirmed judgment by the District Court for the District of Massachusetts dismissing the suit brought by Drs. Berish Rubin and Sylvia Anderson against The...more

Life Sciences Update -- May 2013: Baker & McKenzie

by Baker & McKenzie Australia on 5/3/2013

Increased Regulation of Interactions with Healthcare Professionals - In an effort to increase the transparency of interactions between pharmaceutical companies and health care professionals the new (17th) edition of...more

A Perspective on the Cost of the Myriad BRCA Gene Test

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 5/3/2013

One of the most compelling arguments in the gene patenting debate with the public has been the cost of the Myriad BRCA gene test: $3,000 per test, a price that many without insurance coverage cannot afford. The argument...more

Supreme Debate: Are Human Genes Patentable?

by Therese Finan | Venable LLP on 5/1/2013

On April 15, 2013, tackling an issue of significant importance to the biotechnology and health care industries, the U.S. Supreme Court heard oral arguments over whether human genes are patentable and more specifically,...more

Supreme Court of India Denies Novartis Patent Application

by Amita Gopinath | Miller Canfield on 4/4/2013

In a landmark judgment delivered on April 1, 2013, the Supreme Court of India dismissed an appeal by Novartis AG, a Swiss pharmaceutical giant, to win patent protection in India for its cancer drug Glivec. The polarizing...more

Genome Medicine Article Calls for Limits on Patenting of Existing Nucleotide Sequences

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 4/3/2013

In an article published in the current issue of Genome Medicine, Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Christopher Mason of Cornell University contend that due to the non-specificity of...more

Supreme Court To Hear Oral Arguments in Landmark Patent Case

by Baker, Donelson, Bearman, Caldwell &... on 3/28/2013

April 15 is a big day for biotechnology, pharmaceutical, and medical diagnostic companies at the Supreme Court, as justices begin a new session by hearing oral arguments in a landmark case involving the patentability of...more

Senators Introduce Another Bill to Ban Reverse Payment Settlement Agreements

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 3/15/2013

Last week, Senator Al Franken (D-MN) was joined by Senators David Vitter (R-LA), Dick Durbin (D-IL), Jeanne Shaheen (D-NH), and Bernie Sanders (I-VT) in introducing S. 204, the "Fair and Immediate Release of Generic Drugs...more

WLF Submits Comments on Abbott's Citizen Petition on Biosimilars

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 3/7/2013

Last April, Abbott Laboratories filed a Citizen Petition with the U.S. Food and Drug Administration, asking the agency to refrain from accepting biosimilar applications under the Biologics Price Competition and Innovation Act...more

News from Abroad: Bill to Diminish Term of Patents for Medicaments

by McDonnell Boehnen Hulbert & Berghoff LLP on 3/6/2013

Originally published in Olivares & Cia. on March 4, 2013. In January, the Mexican Senate published a Bill adding article 23 bis to the Industrial Property Law (IP Law). This Bill intends to establish a "special" life...more

New from Abroad: Broadening of UK Bolar Defence

by McDonnell Boehnen Hulbert & Berghoff LLP on 3/6/2013

Originally published in WP Thompson & Co. on March 4, 2013. On 26 February 2013, the UK government announced a proposed change to the Patents Act to exempt clinical and field trials, as well as "health technology...more

Par/Paddock Answers FTC Before Supreme Court

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 2/28/2013

Par PharmaceuticalPar/Paddock, one of the generic drug company defendants in FTC v. Actavis Inc. et al. (the "reverse payment" ANDA settlement case now before the Supreme Court) filed its reponsive brief last week. In it,...more

Court Report -- February 24, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 2/25/2013

In This Issue: Novartis Pharmaceuticals Corp. v. Actavis LLC et al.; Precision Biosciences Inc. et al. v. Cellectis S.A. et al.; Bayer Pharma AG v. Warner Chilcott Co., LLC et al.; Promega Corp. et al. v. Life...more

News from Abroad: Australian Federal Court Upholds Myriad's BRCA1 Gene Patents

by McDonnell Boehnen Hulbert & Berghoff LLP on 2/18/2013

In a significant win for Myriad, and their licensee Genetic Technologies Ltd, the Australian Federal Court on Friday upheld Myriad's method patents used in cancer screening for mutations in the BRCA1 gene. This decision will...more

Court Report -- February 10, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 2/11/2013

In This Issue: Cadence Pharmaceuticals, Inc. et al. v. Sandoz Inc.; Cadence Pharmaceuticals, Inc. et al. v. Sandoz, Inc.; Purdue Pharma L.P. et al. v. Watson Laboratories, Inc. et al.; Purdue Pharma L.P. et al. v....more

January 2013: European Litigation Update

by Quinn Emanuel Urquhart & Sullivan, LLP on 2/6/2013

The European Court of Justice (ECJ) on European Supplementary Protection Certificate (SPC) for Further Medical Uses: With a remarkable ruling from July 2012 (Neurim Pharmaceuticals, C-130/11), the European Court of Justice...more

Annual Venture Funding Drops for First Time in Three Years

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 2/5/2013

Last month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for 2012. The report, which is...more

China Trade Marks – Inclusion of Retail and Wholesale services relating to medicines and pharmaceuticals

by Jonathan Feder, Shalini Jayaweera, Anthony Watson | K&L Gates LLP on 1/21/2013

The China Trade Marks Office (CTMO) recently announced that from 1 January 2013 it is accepting applications to register trade marks in relation to retail or wholesale services for pharmaceutical, veterinary and sanitary...more

FTC Releases Another Report on Reverse Payment Settlement Agreements in ANDA Litigation

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 1/18/2013

As it has frequently in the past decade, the Federal Trade Commission on Thursday released a Report on the frequency of reverse payment settlement agreements in ANDA litigation between generic and branded drug makers,...more

Chinese FDA Unveils Plan for Regulatory Reform

by Katherine Wang | Ropes & Gray LLP on 1/9/2013

The Chinese State Food and Drug Administration (“SFDA”) announced a plan for regulatory reform (“Reform Plan”) and is soliciting public comments through January 15, 2013. The Reform Plan sets forth the following key strategic...more

China Issues Human Genetic Resources Management Regulations

by Foley & Lardner LLP on 11/19/2012

Those seeking to conduct research involving human genetic material within the People’s Republic of China or to import into China such material should review China’s recently issued draft regulations (“Draft”) for the...more

Bring-Your-Own Device Policies Present Special Challenges for the Health Care Sector

by Mintz Levin - Health Law on 10/2/2012

The use of employee-owned devices in the business setting – often referred to as “bring-your-own-device” or “BYOD” – presents data security challenges for all businesses....more

Patent Pool Simplifies Development of Personalized Medicine

by Foley & Lardner LLP on 10/1/2012

One argument often cited against patenting is that multiple patents can cover one product, its preparation and use, creating a so-called “patent thicket” that must be unwound like a bowl of spaghetti before a new technology...more

ACLU Petitions Supreme Court to Review Gene Patenting Case

by Foley & Lardner LLP on 9/27/2012

The ACLU and PUBPAT issued a press release today announcing that they are petitioning the U.S. Supreme Court to review the U.S. Federal Circuit’s decision upholding the patent-eligibility of isolated DNA. The release...more

The Life Sciences Report - Fall 2012

by Wilson Sonsini Goodrich & Rosati on 9/27/2012

In this issue: - First-Mover Advantage: The Case for Investing in Life Science - Medical Device User Fee Amendments of 2012: A Fact Sheet - Life Science Venture Financings for WSGR Clients - Eight...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

Science, Computers & Technology › Intellectual Property › Health Law